Download 11/18/04 Curriculum Vitae - Indiana University School of Medicine

07-08-2015
Curriculum Vitae
MATTSON, DAVID HARRISON, M.D., PH.D.
Office:
Indiana University School of Medicine
IU Health Neuroscience Center
355 W. 16th St.
Indianapolis, IN 46202
Phone: (317)963-7419
Fax: (317)963-7533
email: [email protected]
Home:
4400 Summer Drive
Zionsville, IN 46077
317-769-6854
317-626-0824 (cell)
EDUCATION:
1972-76
Carleton College, Northfield, MN, B.A. in Chemistry (magna cum laude) with honors in
independent study, Phi Beta Kappa, Sigma Xi
1976-82
Medical Scientists Training Program, University of Chicago Pritzker School of Medicine,
Chicago, IL, MD-PhD, Medical Scientist Training Program trainee with Dr. Raymond
Roos
1980
PhD, University of Chicago Pritzker School of Medicine (Committee on Immunology),
Thesis: Studies of oligoclonal IgG in the brains and cerebrospinal fluid of multiple
sclerosis and subacute sclerosing panencephalitis patients
1982
MD, University of Chicago Pritzker School of Medicine, with honors
1982-83
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia,PA
1983-86
Resident in Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA
1985
Honorary Assistant House Physician, The National Hospital, Maida Vale Hospital. Queen
Square, London, England
1986-89
Medical Staff Fellow, Neuroimmunology Branch, NINDS, National Institutes of Health,
Bethesda, MD
ACADEMIC APPOINTMENTS:
1989-95
Assistant Professor, Departments of Neurology, Microbiology & Immunology, University
of Rochester School of Medicine & Dentistry, Rochester, NY
1995-97
Associate Professor, Departments of Neurology, Microbiology & Immunology,
University of Rochester School of Medicine & Dentistry
1997-01
Associate Professor, Department of Neurology, Indiana University School of Medicine,
Indianapolis, IN
2001-present
Professor, Department of Neurology, Indiana University School of Medicine, Indianapolis,
IN
HOSPITAL APPOINTMENTS:
1996-97
Chief, General Neurology Unit, Department of Neurology, University of Rochester School
of Medicine & Dentistry
1996-97
Director, Ambulatory Care, Department of Neurology, University of Rochester School of
Medicine and Dentistry
1997-present
Director. Neuroimmunology/Multiple Sclerosis Program, Indiana University School of
Medicine, Indianapolis, IN
OTHER APPOINTMENTS AND PROFESSIONAL CONSULTANTSHIPS:
Not Applicable
SPECIALTY BOARD STATUS:
American Board of Psychiatry & Neurology, (Neurology) 1987.
LICENSURE AND CERTIFICATION:
State of Pennsylvania - 1983-1989
State of New York - 1989-1997
State of Indiana - 1997-present (license #01046972)
PROFESSIONAL ORGANIZATIONS:
American Academy of Neurology, 1985-present; elected as Fellow 9-07
American Medical Association, 1987-present
Indiana Neurologic Society, 1997-present; Vice President, 2005-2006; President, 2007-2008
Consortium of Multiple Sclerosis Centers, 1997-present
American Neurological Association, 2000-present
HONORS AND AWARDS:
Kate’s Hope Award recipient and Keynote Speaker, Indiana State Chapter, National MS Society, South
Bend, IN, 09/23/2011
Physician of the Year, 2010, Indiana State Chapter, National MS Society Annual Meeting, Indianapolis, IN
Inducted into National MS Society 2007 Volunteer Hall of Fame, for Health Professionals/Researchers
Listed in Best Doctors 2001-2002, 2005, 2007-2008, 2010, 2011-2012, 2013, 2014
Refereed Publication #25 by Mushlin et al. on “The cost effectiveness of magnetic resonance imaging for
patients with equivocal neurologic symptoms” received the 1997 International Society of Technology
Assessment in Health Care award as finest article published in the Int. J. Technology Assess. Hlth.Care
1994 Emotional and Cognitive Award for Cluster D, E, and F, from the National Multiple Sclerosis Society
for the workshop ‘Let’s Talk About MS and Sexuality,” with John Wolf, M.D.
TEACHING ASSIGNMENTS DURING AT LEAST THE PRECEDING TWO YEARS:
Graduate Courses:
Neuroopthalmalogic Manifestations of Multiple Sclerosis; Indiana University School of Optometry,
Bloomington, IN, April 2, 2007; March 24, 2008; March 23, 2009; March 22, 2010, 02/07/2011,
02/06/2012, 2/18/2013, 2/3/2014, 1/26/2015
Graduate Student Supervision:
2010-2012 Clinical Mentor, Gary Leung, Clincial and Translational Science Institute Grant Award
1998
Railroad Apache. PhD Thesis collaborator. Indiana University-Bloomington, Department of
Kinesiology, Chairman of PhD thesis committee. [supervise and critique research project- 5 hrs
per week]
1995 Caroline Little. Member of Masters Thesis Committee. Department of Neurobiology & Anatomy,
University of Rochester
1995 Julia Chang. Chairman, PhD Examination Committee. Department of Neurobiology & Anatomy
University of Rochester
1995 Kevin Kinney. Chairman, PhD Examination Committee. Neuroscience Program, University of
Rochester
1991 Linda Metheny. Program in Biology and Medicine. Supervised laboratory rotation, University of
Rochester
1991 Lieh-bang Liow. Member of Masters Thesis Committee. Department of Microbiology &
Immunology, University of Rochester
Medical School Course:
Introduction to Clinical Neurology-small group session on neurologic exam, Indiana University School of
Medicine, 3/2/98, 11/15/99, 1/10/02, 11/25/02, 10/14/09, 10/22/2012, 10/16-10/17/2013. [3 hrs per year, 5
students in group]
Multiple Sclerosis. Core Neurology Clerkship Lecture Series. Indiana University School of Medicine,
monthly lectures, 10/97- 12/05. [1 hr each month]
Medical Student Supervision:
1995
Kathy Barett. Supervised Year Out project, University of Rochester
1994
Elizabeth VanDelinde. Supervised Strong Children’s Research Center Fellowship, summer
project, University of Rochester
1992
Joy Bottoms. Supervised Medical Student Summer Research Fellowship, summer project,
University of Rochester
House Staff Education (since 2005):
MS diagnosis and differential diagnosis, Neurology resident morning report, 7/22-7/24, 2014
Update on MS for Psychiatry Residents, Psychiatry Power Hour, Indiana University School of Medicine,
October 28, 2011
Update on MS, Neurology/Neurosurgery resident conference, Indiana University School of Medicine,
March 10, 2010
Topics in Multiple Sclerosis, Neurology resident morning report, Indiana University School of Medicine,
monthly sessions, 2004 - present
Update on Multiple Sclerosis, PM & R Resident Conference, IU School of Medicine, Indianapolis, IN,
April 17, 2006; March 16, 2009; October 24, 2011; May 20,2013
ADEM/Childhood Multiple Sclerosis, Pediatric Neurology Conference, Riley Children’s Hospital,
Indianapolis, IN, February 14, 2006; February 26, 2008, March 13, 2013
House Staff Supervision:
2013-2014
Advisor, clinical project, Adam Comer, Neurology Resident
2011-2013
Advisor, Ross Paper Clinical Project, Sara Isis Delima, M.D., Neurology Resident
2006-2007
Advisor, Ross Paper Clinical Project, Melissa DeRosa, M.D., Neurology Resident
2004-2005
Advisor, Ross Paper Clinical Project, Jay Bhatt, M.D., Neurology Resident
2003-2011
Supervisor, Internal Medicine Resident (outpatient neurology rotation), [1 half day per
month]
2001
Fabio Iwamoto, MD, Brazilian visiting resident externship
2013-present
Attending, IU Health Methodist and University Hospitals
1997-2012
Ward or consult attending at Indiana University Medical Center or Wishard Hospital.
[3 months per year, supervising team of 1 or 2 neurology residents and 2 to 5 students]
1997-present
Supervisor, Ambulatory Rotation Resident, Indiana University Multiple Sclerosis Clinic [4hours of clinical supervision each week — one resident and one student at a time]
1995-96
Attending, General Neurology residents’ firm, University of Rochester
1992-93
Peter Calabrese, MD, Resident in Neurology. University of Rochester, Co-supervised
clinical research project involving very long chain fatty acid abnormalities in MS patients.
Post-graduate Supervision:
2014
Matthew Larson, OD, 1 day observership for optometry fellow from IU School of
Optometry
7/2012-3/2013 Jaison Grimes, MD, post-doctoral MS Clinical fellow, Biogen-Idec sponsored
2013
Lucy Kehinde, OD, 1 day observership for optometry fellow from IU School of Optometry
2012
Dawn Meyer, OD, 1 day observership for optometry follow from IU School of Optometry
2010
Monica Kalia, OD, 1 day observership for optometry fellow from IU School of Optometry
8/08-12/08
Brooke Huber, RN, Nurse Practitioner Masters Degree Program Preceptorship (5
hours/week)
2002
Frank Skidmore, MD, post-doctoral fellow
2001
Preceptorship, Marc Petitclerc, MD, and Donald Rivest, MD Montreal, Canada
2001
Observership, Megan McCarty, RPT
2000
Preceptorship, Odd Almstrom, MD, and Ann-Sophie Svanberg, Varberg, Sweden
1994-96
Steven Schwid, MD, post-doctoral fellow. Experimental Therapeutics Training Grant,
University of Rochester, Supervised projects involving effects of pulse steroids on bone
density and treatment of fatigue with pentoxyfilline in MS patients, and antioxidant
therapy in MS
Undergraduate Education:
Undergraduate Supervision:
2012
Eric Krueger, premedical student preceptorship, summer, 1 day per week
2000
Annie Lynch and Rebecca Kuhnlein. Premedical Student Sponsorship. Indiana University
undergraduate premedical students
1998-99
Dean Kincaid. Supervising independent study project. Indiana University-Purdue
University-Indianapolis psychology major. [1 hr per week]
1995-96
Robert Collard. Supervised independent study project. University of Rochester biology
major
1994-95
Richard Koehler. Supervised Senior Scholars project. University of Rochester
biochemistry major
1994-95
Imran Qureshi. Supervised Senior Scholars project. University of Rochester molecular
genetic major
1994
Susan Barned. Supervised winter and spring break research project. Grove City College
biology major
1991
Darci Nealson. Supervised summer independent study research project.
Rochester neuroscience major
1990-91
Andrea Moyer. Supervised research project. University of Rochester Psychology and
English major
University of
Continuing Medical Education (Since 2005):
Caught in the crossfire: Regaining control of MS care. Panel discussant. Consortium of MS Centers
Annual Meeting, Indianapolis, IN, 5/29/2015
Multiple sclerosis-- Updates on diagnosis, therapies, and rheumatologic complications. Rheumatology
Grand Rounds, Indiana University School of Medicine, 4/14/2015
Course Director, Neurology Update for Neurologists IV, all day CME course, Indiana University School of
Medicine, Indianapolis, IN, 11/15/2014
Treatment of MS relapses. Questcor dinner program, Indianapolis, IN, 7/23/2014
Update on diagnostic criteria for multiple sclerosis. CME lecture series, IU Health Bloomington Hospital,
Bloomington, IN, 4/2/2014
Building a contemporary treatment strategy: A new option for relapsing forms of MS. Teva physician
program, Indianapolis, IN, 3/13/2014
Multiple sclerosis update from ECTRIMS. Neuroscience grand rounds, IU Health Neuroscience Center,
Indianapolis, IN, 1/29/2014
5th Annual updates from ECTRIMS. Highlights in research and treatment of multiple sclerosis. PRIME
CME, Indianapolis, IN, 1/28/2014
Tecfidera condensed safety and efficacy overview. Biogen-Idec physician program, Indianapolis, IN,
1/22/2014
Neurology Update for Neurologists III. All day CME course, Indiana University School of Medicine,
Indianapolis, IN, 12/7/2013
Proven efficacy across three disease measures in relapsing MS. Pfizer physician program, Kokomo, IN,
11/20/2013
A group discussion of a journal article in Neurology. Genzyme journal club. Columbus, IN, 11/7/2013
The transition to oral medications for multiple sclerosis. 12th annual meeting of the Indiana Neurological
Society, Indianapolis, IN, 10/11/2013
Ampyra peer-to-peer speaker webinar.
7/11/2012,11/28/2012,12/5/2012,12/6/2012,12/12/2012,12/13/2012 (2),12/19/2012 (2),12//2/2012,
3/12/2013, 3/3/2014, 3/5/2014, 4/9/2014, 4/16/2014.
An overview of Gilenya ( fingolimod). Indianapolis, IN, 6/21/12012; Indianapolis, IN, 7/24/2012,
Evansville, IN, 10/31/2012; Louisville, KY,10/31/2012; Indianapolis, IN, 11/21/2012; Indianapolis, IN,
11/29/2012; Indianapolis, IN, 12/6/2012, Bloomington, IN 1/2/2013; Richmond , IN, 2/21/2013
Ampyra peer to peer speaker program, Baltimore, MD, 6/26/2013; Glen Burnie, MD, 6/27/2013,
Building a sustainable treatment strategy, Teva physician program, Kokomo, IN, 6/20/2012; Avon,
IN,6/27/2012; Carmel, IN, 7/19/2012; Muncie, IN, 9/19/2012; Columbus, IN, 10/11/201; Terre Haute, IN
10/17/2012; Indianapolis, IN 10/24/2012; Bloomington, IN 10/25/2012; Richmond, IN 1/9/2013;
Indianapolis, IN, 1/24/2013; Avon , IN,1/31/2013; Indianapolis, IN 2/13/2013; Kokomo, IN, 4/25/2013.
Navigating options in RRMS, Teva physician program. Indianapolis, IN 5/8/2013; Avon, IN 5/15/2013;
Indianapolis, IN 5/22/2013; Terre Haute, IN 5/23/2013; Muncie, IN, 8/29/2013
MS: An exchange in patient management . EMD Serono journal club Indianapolis, IN 10/24/2012
Proven efficacy across three disease measures in relapsing MS. EMD- serono and Pfizer Physician
program. Cleveland, OH, 11/7/2012, Indianapolis, IN 2/20/2013, Indianapolis, IN 8/21/2013.
Importance of adherence in patients with relapsing multiple sclerosis. Pfizer Physician program,
Indianapolis, IN, 5/9/2012; Lafayette, IN 1/10/2013.
Overview of Gilenya (Fingolimod) and Cardiovascular Considerations, Indianapolis, IN, 12/3/2012.
Change in the multiple sclerosis landscape, Genzyme physician program. Indianapolis, IN, 11/19/2012.
Unleash the Fighter – Tysabri. Biogen – Idec physician talk. Terre Haute, IN, 11/20/2012; Bloomington,
IN, 12/12/2012; Lafayette, IN, 1/30/13; Evansville, IN, 4/10/2013; Jasper, IN, 4/10/2013.
Aronex update. Biogen – Idec physician talk. Indianapolis, IN, 12/20/2012
Optimizing discussions with MS patients, EMD – Serono physician program, Indianapolis, IN, 12/17/2012.
Multiple Sclerosis: Update on diagnostic Criteria, treatments, and treatment paradigm. The Stanley
Wissman Neuroscience/ Brain Injury symposium, Ft Wayne, IN 11/15/2012.
Introducing two new innovations. Biogen –Idec physician talk. Indianapolis, IN 8/21/2012
Progressive multifocal leukoencephalapathy, Stratify -2 JC virus antibody test Biogen – Idec physician
talk. Bloomington, IN, 2/14/2013
Tecfidera Biogen – Idcc physician talk. Indianapolis, IN, 5/9/2013; Avon, IN, 6/5/2013; Bloomington, IN,
6/16/2013; Indianapolis, IN, 7/24/2013
Treating MS in 2013, Neuroscience Grand Rounds. IU Health Neuroscience Center, Indianapolis, IN,
5/1/2013.
Course Director, Neurology Update for Neurologists II, all day CME course, Indiana University School of
Medicine, Indianapolis, IN 11/10/2012
MS Consensus 2012 from research to practice. ProCE CME talk, Indianapolis, IN, 6/18/2012
Treating Multiple Sclerosis in 2012 and Beyond. What will we do with all these choices! Clinical
Neuroscience Grand Rounds, Indiana University School of Medicine, January 12, 2012
Efficacy across a range of patients with relapsing MS. EMD-Serono, Indianapolis, IN, December 8, 2011
Vitamin D as an Autoimmune Modulator in Multiple Sclerosis, A Review, EMD Serono Journal Club,
Indianapolis, IN, December 5, 2011
Updates from ECTRIMS: Highlights of Presentations from the 5th Joint Triennial Congress. PrimeInc
CME, Indianapolis, IN, December 1, 2011
Constructing an Adaptive Care Model for the Management of Disease-Related Symptoms throughout the
course of Multiple Sclerosis. Peer View Institute, Academy for Health Care Learning CME preceptor ship,
Waddell MS Center, University of Cincinnati OH November 9, 2011
MS: An Exchange in Patient Management, The Psychology of Fatigue in Patients with Multiple Sclerosis.
EMD Serono Journal Club, Indianapolis, IN, November 1, 2011
Course Director, 10th Annual Meeting of the Indiana Neurological Society, Indianapolis, IN, October 14,
2011
Update on Multiple Sclerosis (MS) for Primary Care. Grand Rounds, Reid Hospital, Richmond, IN Sept
21, 2011
Cutting Edge 2011: Research update in Multple Sclerosis. ProCE CME, Indianapolis, IN, June 29, 2011
Case Report: Anoxic Encephalopathy. Clinical Neuroscience Grand rounds. Indiana University School of
Medicine, June 16, 2011
Gilenya (fingolimod) and the date supporting its use. Novartis Pharmaceutical Promotional Speaker
Program; Anderson IN, May 19, 2011; Indianapolis IN, July 21, 2011; Columbus IN, July 28, 2011;
Indianapolis IN, August 2, 2011; Indianapolis IN, September 7, 2011; Indianapolis IN, September 21,
2011; Bloomington IN, October 27, 2011; Danville IN, February 9, 2012; Richmond IN, March 22, 2012
Multiple Sclerosis Highlights in the field. 63rd AAN Annual Meeting, Honolulu, Hawaii, April 13, 2011
Neurology Update for Neurologists, Course Director, Indiana University School of Medicine full day CME
Course, Indianapolis IN, March 5, 2011
New Advances and Treatment in Multiple Sclerosis, Neurology Update for Neurologists CME Course,
Indianapolis IN, March 5, 2011
Amprya Physician Programs; Lafayette IN, September 1, 2010; Richmond IN, September 30, 2010;
Ypsilanti MI, December 9, 2011; Jackson MI, December 9, 2010; Evansville IN, January 1, 2011
Immunologic Pathways in RRMS treatment, Teva Neuroscience Physician Program; January 1,2011;
Indianapolis IN, May 12, 2011; Indianapolis IN, July 20, 2011; Muncie IN, August 17, 2011; Indianapolis
IN, November 2, 2011; Terre Haute IN, October 26, 2011; Indianapolis IN, November 2, 2011
Efficacy across a range of patients with relapsing MS. Pfizer Promotional Program. Lafayette IN
December 15, 2010; Kalamazoo MI, December 2, 2010
Update on MS. The Oral Era in MS Begins (Sort Of)….Clinical Neuroscience Grand Rounds, Indiana
University School of Medicine, November 4, 2010
Therapeutic Update in Multiple Sclerosis, Biogen Idec Physician Talk, Indianapolis IN, October 12, 2010
Changing Perspective and Expanding Treatment approaches in RRMS, Teva Neurosciences Physician
Program. Terre Haute IN, October 7, 2010
Recognizing and Managing Multiple Sclerosis & Constructing a Continuum of Care. Peer View Institute
CME. Indianapolis IN, September 25, 2010
Cutting Edge 2010; Research Updates in Multiple Sclerosis. ProCe CME, Indianapolis IN, September 21,
2010
Treatment of Early MS: 5-year results from the BENEFIT study. Bayer Speaking engagement.
Indianapolis, IN, August 17,2010
MS Emerging Therapies, Teva Neuroscience regional business meeting, July 21, 2010
MS Update, Teva Physician Program, Fort Wayne, IN, January 27, 2010; Bloomington, IN, January 28,
2010; Columbus, IN, February 25, 2010; Avon, IN, March 24, 2010; Indianapolis, IN, July 14, 2010
Maximizing Outcomes in Multiple Sclerosis: Integrating Novel Strategies Into Today’s Treatment
Armamentarium, Center for Medical Knowledge CME dinner meetings, Indianapolis, IN, June 9, 2010,
Springfield, IL:, June 23, 2010
Discussion surrounding a treatment for today’s RRMS patient, EMD Serono physician talk, Las Vegas,
NV, June 18, 2010
Multiple Sclerosis journal clubs- venous insufficiency, EMD Serono, Chicago, IL May 5, 2010;
Indianapolis, IN, June 17, 2010
The Importance of Adherence to MS Therapy, Pfizer physician programs, Avon, IN, April 21, 2010,
Indianapolis, IN, May 13, 2010
Progress in Understanding and Treating the Multiple Mysteries of Multiple Sclerosis, Invited lecture,
Eleventh Annual Thomas P. Kuneger Neuroscience Symposium, Deaconess Hospital, Evansville, IN,
April 20, 2010
Multiple Sclerosis Update, Biogen Idec dinner program, Indianapolis, IN, February 25, 2010
Multiple Sclerosis Journal Club- MS grey matter involvement, Indianapolis, IN, February 16, 2010
Tradeoffs in Multiple Sclerosis Therapeutics, Clinical Neuroscience Grand Rounds, Indiana University
School of Medicine, January 7, 2010
Efficiency across a Range of Patients with Relapsing MS, Pfizer physician programs, St. Louis, MO,
October 15, 2009; Cleveland, OH, November 5, 2009; Indianapolis, IN, November 9, 2009; Kokomo, IN,
December 11, 2009
MS Update, Teva physician programs, Avon, IN, July 8, 2009; Granger, IN, July 15, 2009, Carmel, IN,
September 16, 2009; Fishers, IN, October 20, 2009:, Avon, IN, November 4, 2009; Indianapolis, IN,
November 11, 2009
MS Update, EMD Serono physician programs, Birmingham, MI, July 9, 2009; Danville, IN, August 12,
1009; Indianapolis, IN, October 7, 2009; Westlake, OH, November 5, 2009
Clinically Isolated Syndromes : Treatment Considerations, Biogen Idec lunch program, Indianapolis, IN,
August 19, 2009
MS Update, Biogen Idec lunch program, Fort Wayne, IN, July 15, 2009
Discussion Surrounding Treatment for Today’s RRMS Patient, Serono PhysicianTalks, Fayettville, AR,
July 22, 2008, Fort Smith, AR, July 23, 2008, Columbus, IN, August 4, 2008, Indianapolis, IN, March 18,
2009, Avon, IN, April 8, 2009, Evansville, IN, June 23, 2009
MS Therapy Update and Treatment Considerations, Teva Physician Programs, Indianapolis, IN, July 3,
2008, Bloomington, IN, August 28, 2008, Indianapolis, IN, October 1, 2008, Avon, IN, October 9, 2008,
Danville, IN, November 6, 2008, Fort Wayne, IN, January 14, 2009, Indianapolis, IN, February 25, 2009,
Muncie, IN, May 20, 2009, Indianapolis, IN, June 17, 2009, June 18, 2009
Balancing Performance and Safety in RRMS, Pfizer Physician Programs, Fishers, IN, August 28, 2008,
Muncie, IN, October 15, 2008, Indianapolis, IN, March 12, 2009, Cincinnati, OH, March 25, 2009,
Indianapolis, IN, March 26, 2009
Journal Club for Serono MSL, Chicago, IL, March 4, 2009
MS Update: Recent and ongoing head-to-head clinical trials that are changing how we treat and study
MS, Clinical Neuroscience Grand Rounds, Indiana University School of Medicine, January 22, 2009
Tysabri Update, Biogen Physician Talk, Carmel, IN, October 2, 2008
Balancing Performance and Safety in RRMS, Serono dinner panel presentation /discussion, Lombard, IL,
May 6, 2008
A Discussion Surrounding Treatment for Today’s RRMS Patient, Pfizer lunch talk, Indianapolis, IN, May 2,
2008
Clinical Considerations in Managing RRMS, Serono lunch program, Terre Haute, IN, November 21, 2007;
Bloomington, IN, December 19, 2007; Terre Haute, IN, April 25, 2008; Richmond, IN, May 15, 2008;
Evansville, IN, June 25, 2008
Therapeutic Advances in MS, Serono dinner program, Tampa, FL; November 7, 2007; Clearwater, FL,
November 8, 2007; Evansville, IN, November 14, 2007
Patient Management, Therapy and Treatment Optimization, Pfizer dinner talk, Paducah, KY, November
14, 2007
Multiple Sclerosis Panel Debate: Controversies and Dilemmas in Care, Jacksonville, FL, November 8,
2007
Update on Copaxone, Teva lunch seminars, Bloomington, IN, 7/262007; Indianapolis, IN, 9/13/07,
9/27/07, 10/3/07, 10/10/07, 11/7/07, 12/5/07, 3/12/08, 3/20/08; Richmond, IN, 5/28/2008
Multiple Sclerosis Case Based Studies, 6th Annual Meeting of the Indiana Neurological Society,
Indianapolis, IN, September 28, 2007
Multiple Sclerosis, Program Co-Chairperson and Moderator for 6th Annual Meeting of the Indiana
Neurological Society, Indianapolis, IN, September 28, 2007
Why High Dose High Frequency Interferon Therapy Is Important, Pfizer dinner talks, Louisville, KY,
August 15 and 16, 2007
Multiple Sclerosis Update – Past, Present, and Future, Clinical Neuroscience Grand Rounds, IU Medical
Center, Indianapolis, IN, August 3, 2007
MS Crossfire, Serono Roundtable symposium, Rosemont, IL June 28, 2007
Why High Dose, High Frequency Interferon therapy is Important in RRMS, Pfizer/Serono Medical
Education Dinner Program, Evansville, IN, June 27, 2007; Ft. Wayne, IN, (2 talks), February 28, 2007;
Columbia, MO, February 21, 2007; St. Louis MO, February 22, 2007; Lexington, KY (2 talks), January 17,
2007; Springfield and Joplin, MO, January 10-11, 2007 (3 talks)
Update on MS and Copaxone, Teva lunch seminar, Indianapolis, IN, June 7, 2007
The Importance of Early and Aggressive Treatment in the Management of Relapsing Forms of Multiple
Sclerosis, Berlex Dinner Program, Indianapolis, IN, May 23, 2007
Mechanism of Action of Tysabri and Patient Selection and Case Studies, Biogen-Idec Physician
Consultants meeting, Detroit, MI, November 18, 2006
Importance of Early High Dose High Frequency Rebif Therapy for Relapsing Forms of MS, Pfizer/Serono
Medical Education lunch program, Indiana Neuro Science Association, Indianapolis, IN, October 9, 2006
Update on MS and Copaxone, Teva lunch seminar, Avon, IN, November 9, 2006, September 28, 2006
Multiple Sclerosis – Diagnosis, Treatment, and the Future, invited lecturer, The Stan Wissman
Neuroscience Symposium , Ft, Wayne, IN, October 19, 2006
The Importance of Early and Aggressive Treatment in the Management of Relapsing Forms of Multiple
Sclerosis, Berlex Dinner Program, Indianapolis, IN, September 28, 2006
Why high-Dose, High Frequency Interferon Therapy is Important in RRMS, Pfizer/Serono Medical
Education Dinner Program; Indianapolis, IN, July 20, 2006; Lexington, KY, July 26, 2006; Evansville, IN,
July 27, 2006
Update on MS, Columbus NeuroScience, Columbus, IN, April 19, 2006
Rational for Treatment at Diagnosis, Biogen-Idec talk, Indianapolis, IN, April 12, 2006
Multiple Sclerosis: Clinical Challenges and Controversies, In Neuro Crossfire I, CME course at American
Academy of Neurology meeting, San Diego, CA, April 7, 2006
Rationale for Early, High Sustained Rebif, Serono/iMeetings talk, Bloomington, IN, February 15, 2006
Update on Diagnosis and Treatment of MS, Serono/iMeetings talks; Louisville, KY (x2), January 25, 2006;
Lexington, KY (x2), January 26, 2006
MS update, lunch round table, JWM Neurology East, Indianapolis, IN, December 1, 2005
Impact of Multiple Sclerosis Therapies on Brain Atrophy, Atrophy/Neuroprotection discussion, BiogenIdec. Consultants meeting, Dearborn, MI, October 22, 2005
Multiple Sclerosis Immunotherapy: Case-based approach, MS Roundtable, Peoria, Il, Danville, IL October
19, 2005
Mechanism of Action: Natalizumab, Biogen Physician Consultant meeting, Orlando, FL., April 30, 2005
Multiple Sclerosis: Clinical Challenges and Controversies, in Neuro – Crossfire I; CME Course at
American Academy of Neurology meeting, Miami, FL, April 11, 2005
Multiple Sclerosis, CME Medical Education Conference, Union Hospital, Terre Haute, IN, February 10,
2005
Update in Multiple Sclerosis – Tysabri; Teleconferences; Midwest Neurology Associates, Evansville, IN,
December 14, 2004; JWM Neurology, Indianapolis, IN, January 20, 2005; Ft. Wayne Neurology, Ft.
Wayne, IN, January 27, 2005; JWM Neurology South, Indianapolis, IN, February 8, 2005; February 8,
2005; JWM Neurology St. Vincent’s, Indianapolis, IN, February 1, 2005
Update in Multiple Sclerosis, Clinical NeuroScience Grand Rounds, Indiana University School of
Medicine, Indianapolis, IN, January 6, 2005
Immunotherapy of MS, Philippines Neurological Association, Baguio City, Philippines, November 13,
2004
The Neurobiology and Neuroimmunology of Central Demyelinating Disorders, Gilberto Gamez, M.D.
Memorial Lecture (invited lecture), Philippines Neurological Society, Baguio City, Philippines, November
12, 2004
(1) Service to the Discipline:
(a) State and Regional:
2005-2006
2006-2008
2008-2010
2010-2012
2012-present
Vice President, Indiana Neurologic Society
President, Indiana Neurologic Society
Past President, Indiana Neurologic Society
Chair, Education Committee, Indiana Neurological Society
Member, Education Committee, Indiana Neurological Society
(b) National and International:
2014-present
Past chair/councilor, MS Section Executive Committee, American Academy of Neurology
2012-2014
Chair, MS section, American Academy of Neurology
2010–2012
Vice Chair, MS Section Executive Committee, American Academy of Neurology
2008-2010
Councilor, MS Section Executive Committee, American Academy of Neurology
3/08, 2/11,2/12 Participant, Neurology On-The-Hill, Washington, D.C.
2004
Ad hoc reviewer: Multiple Sclerosis
2001
Ad hoc reviewer: The Female Patient
2000-2007
Member, American Board of Psychiatry and Neurology Part I exam committee
1998-present
Member, American Board of Psychiatry and Neurology Part II examiners panel
1998
1997
Member Local Arrangements Committee, ABPN Part II Exam, Indianapolis, IN,
November 21-22, 1998
Ad hoc reviewer, National Multiple Sclerosis Society, Grant Review Committee C
1997-present
Editorial Panel, Neurology Review
1989-present
Ad hoc reviewer: Archives of Neurology; Journal of Neuroimmunology; Brain, Behavior,
and Immunity; Mayo Clinic Proceeding; Neurology; Journal of Neurological Science;
Journal of Clinic Outcomes Management
(2) Service to patients/clients and related clinical institutions (patient talks since 2005):
2008-2012
Member, Executive Committee, National Clinical Advisory Board, National MS Society,
New York, NY
2006
Member, Ad hoc committee to review grant on Atorvastatin in MS, National Multiple
Sclerosis Society, New York, NY
2006-present
Member, Oversight Committee, National MS Society Pediatric MS Centers Initiative
2005
Member, Ad hoc committee to review grants for pediatric Multiple Sclerosis Centers,
National Multiple Sclerosis Society, New York, NY
2002-present
Member, Advisory Group, National MS Society funded project-“Aging with
MultipleSclerosis: Unmet needs in the Great Lakes Region”
2002-present
Member, Clinical Care Committee, National MS Society, New York, NY.
2002-present
MD-on-call for Professional Research Center of National MS Society, New York, NY.
[23 different weeks of electronic availability, Q & A for physician and patient inquiries]
2001-present
Chair, Clinical Advisory Committee, Indiana State Chapter, National MS Society
1999-present
Member, International Advisory Board, Argentinian Association to Combat MS.
1998-present
Member, Board of Trustees, Indiana State Chapter, National MS Society
1997-present Attending Physician, Indiana University MS Clinic (4 half days per week), Wishard MS
Clinic (1 half day per month)
1997-present Member, Professional Advisory Committee, Indiana State Chapter, National Multiple
Sclerosis Society
Patient talks
Research update in MS. Annual Board of Trustees meeting, Indiana State Chapter of the National MS
Society, Indianapolis, IN, 10/25/2014
Therapy options: The first step in making a difference. Teva Shared Solutions patient program,
Indianapolis, IN, 2/20/2014
Taking stock of you. EMD-Serono patient program, Indianapolis, IN, 6/18/2014
Sounds like a plan: Could having a plan for your relapsing MS help you feel more in control? Pfizer
patient program, Carmel, IN, 2/18/2014
Living with multiple sclerosis: The importance of health and wellness practices. Bayer patient program,
Indianapolis, IN, 12/10/2013
Understanding and helping to manage common symptoms of multiple sclerosis. Bayer patient program,
Indianapolis, IN, 11/5/2013
Gilenya patient satellite broadcast, Carmel, IN, 5/19/2013.
SRSLY, I don’t have time for the challenge of relapsing MS. EMD – Serono patient program. Terre Haute,
IN, 10/17/2012, Louisville, KY 5/16/2013.
How can I keep moving forward when I’m too tired to think straight? EMD-Serono patient program.
Louisville, KY 5/16/2013
Selected topics in relapsing MS. Pfizer patient program. Indianapolis, IN, 5/23/2013
If I knew if is me or my MS. Pfizer patient program, Indianapolis, IN, 1/23/13; Owensboro, KY 2/7/2013,
Evansville, IN 2/7/2013
If I knew what my healthcare team and I should expect from each other, Pfizer patient program.
Indianapolis, IN, 4/11/2013: Greenwood, IN, 4/24/2013
Adapting with MS. Pfizer patient program. Indianapolis, IN, 7/15/2013; Avon, IN 4/20/2013
Patient Empowerment program, Biogen- Idec patient program, Jasper, IN 4/10/2013
Taking a closer look at relapsing multiple sclerosis. Bayer patient program. Indianapolis, IN, 8/6/2013
Recent research updates in multiple sclerosis patient program. Indiana State Chapter, National Multiple
Sclerosis Society. Indianapolis, IN, 3/12/2013; Bloomington, IN, 6/13/2013.
Gilenya Go patient program. Carmel, IN, 3/6/2012; Kokomo, IN, 3/13/2012; Terre Haute, IN, 4/18/2012,
Bloomington, IN, 5/2/2012; Carmel, IN, 6/12/2012; Indianapolis, IN. 7/21/2012
Ampyra, Terre Haute, IN, 10/4/2012.
Advances in Multiple Sclerosis and current therapies, Teva patient program. Indianapolis, IN, 5/31/2012
Consideration in treatment selection, Pfizer patient program. Evansville, IN, 5/16/2012
If I knew how my MS treatment is clinically proven – EMD Serono and Pfizer patient program.
Greenfield, IN, 6/28/2012; Indianapolis, IN, 9/26/2012; Westlake, OH, 11/18/2012
Importance of Adherence in Patients with Relapsing Multiple Sclerosis. Pfizer, Lafayette IN, January 25,
2012
Selected Topics in Relapsing MS. Pfizer, Ft. Wayne IN, March 10,2011; Greenwood IN, Febuary 8, 2012;
Greenwood IN, February 8, 2012; Lafayette IN, March 19, 2012
Talk MS Live! Taking Care of the Skin You’re in. MS Lifelines Program Indianapolis IN, December 6, 2012
A treatment option for MS, Gilenya GO Novartis Patient Education Program, Indianapolis IN, September
8, 2011; Indianapolis IN, October 27, 2011; Carmel IN, December 12, 2011; Lafayette IN, January 18,
2012; Indianapolis IN, March 6, 2012; Kokomo IN, March 13, 2012
Considerations in treatment, EMD Serono, Anderson IN, November 20, 2011
Selected topics in Relapsing MS. EMD Serono, Greenfield IN, November 8,2011; Terre Haute IN,
November 15, 2011
Talk MS Live! Making Sense of MS. MS Lifelines Program. Louisville, KY, November 10, 2011
MS update, Golden Circle Program, Indiana State Chapter, National MS Society, Indianapolis IN, August
25, 2011
Understanding Relapsing MS. MS Lifelines Webcast, Indianapolis IN, May 18, 2011
Recent Research Update in Multiple Sclerosis Indiana State Chapter, National MS Society. Indianapolis
IN, April 26, 2011
How is your MS being managed? Overcoming some of the challenges of living with MS. Indianapolis IN,
March 15, 2011.
Ampyra patient talks; Lafayette IN, November 11, 2010; Evansville IN, January 12, 2011; Lafayette IN,
March 2, 2011
Therapeutic Updates in Multiple Sclerosis; MS Active Source Educational Series, Indianapolis IN,
February 23, 2011
Clinical Trials and Research on the Horizon. Midwest Teleconference Series. National MS Society,
February 14, 2011
Conserations in treatment selection. Pfizer, Kalamazoo MI, December 2, 2010
Take a closer look at MS. Bayer Speaking engagement, Indianapolis IN, November 15, 2010
Research Update, Let’s Tackle MS! 56th Annual Meeting, Indiana State Chapter, National MS Society,
November 13, 2010
Up all night; MS and Sleep. MS Lifelines webcast, Boston MA, August 26, 2010
Taking control of your Relapsing MS. EMD Serono, San Jose CA, August 14, 2010
Relapsing MS and its management. EMD Serono, Pleasanton CA, August 12, 2010; San Franciso CA,
August 13, 2010
Hot Topics VII, Tristate MS Association, Evansville, IN, June 21, 2010
Taking Control of your Relapsing MS, MS Lifelines patient talk, Henderson, NV, June 19, 2010
Relapsing MS and Its Management, MS Lifelines patient talk, Las Vegas, NV, June 18, 2010
MS Research Update, Indiana State Chapter, National MS Society, Bloomington, IN, June 8, 2010
Make My Day: Improving Your Quality Of Life With MS, MS Active Source, Indianapolis, IN, April 21, 2010
Examining the Evidence: MS Therapy Selection, EMD Serono, Bloomington, IN, April 6, 2010
Talk MS Live, Local Patient Outreach Program, EMD Serono, Las Vegas, NV, December 12, 1009
Examining the Evidence: MS Therapy Selection, EMD Serono, Indianapolis, IN, September 28, 2009;
Greenwood, IN, October 29, 1009
MS Update dinner program, EMD Serono, St. Louis, MO, October 15, 2009
Talk MS Live, Local Patient Outreach Program, EMD Serono, Baltimore, MD, September 30, 2009
Research Update: Directions in MS Research, Indiana State Chapter, National MS Society, Terre Haute,
IN, August 27, 2009
MS Update, Indianapolis Join the Movement Luncheon, Indiana State Chapter, National MS Society,
Indianapolis, IN, July 22, 2009
MS Research Update, Board of Trustees Meeting, Indiana State Chapter, National MS Society,
Indianapolis, IN, June 29, 2009
Hot Topics VI, Tri-State MS Association, Evansville, IN, June 24, 2009
Examining the Evidence: MS Therapy Selection, MS Patient Program, Merrillville, IN, May 7, 2009
Thinking It Through: The Impact of MS on Your Cognitive Function, MS Active Source Patient Program,
Indianapolis, IN, March 26, 2009
MS Unplugged: Real Talk About Treating Your MS, Pfizer Patient Program, Indianapolis, IN, December
13, 1008
Living in Balance With Your MS, MS Lifelines Patient Program, Carmel, IN, December 4, 2008
MS Research Update, Patient Program, Indiana State Chapter, National MS Society, Indianapolis, IN,
September 15, 2008
MS Research and Research Opportunities, Patient Program, Louisville Comprehensive MS Care Center,
Louisville, KY, June 26, 2008
Hot Topics V, Tri-State MS Association, Evansville, IN, June 25, 2008
Recognizing Relapses, Patient Educational Program, Indiana State Chapter, National MS Society,
Indianapolis, IN, June 24, 2008
MS Patient Program, Biogen-Idec, Indianapolis, IN , February 27, 2008
Research Update, Indiana State Chapter, National MS Society, Indianapolis, IN, September 17, 2007
Hot Topics IV, Tri-State MS Association, Evansville, IN June 27, 2007
It Takes a Team to Survive the Holidays, Tri-State MS Association, Evansville, IN, December 13, 2006
Advances in the Treatment of Multiple Sclerosis, MS Active Source Patient Seminar, Plainfield, IN,
November 29, 2006
What’s New for Treatment and Symptom Management, Midwest Teleconference Series, National Multiple
Sclerosis Society, October 9, 2006
MS: Symptom Management, Southern Indiana/Northwestern Kentucky teleconference, IN State Chapter,
National MS Society; August 22, 2006
Hot Topics in MS III, Tri-State MS Association, Evansville, IN, July 27, 2006
Hot Topics in MS, Louisville Comprehensive Care MS Center patient information session, Louisville, KY,
July 26, 2006
Hot Topics in MS, Self Help Group Talk, IN State Chapter, National MS Society, Elkhart, IN, June 7, 2006
MS: Current Developments in Diagnosis and Management, MS Association of America patient
information seminar, Indianapolis, IN, April 29, 2006
Moving Forward with MS: Symptoms, Diagnosis and Treatment Options, IN State Chapter, National MS
Society, Indianapolis, IN, March 8, 2006
Hot Topics in MS II, Tri-State MS Association, Evansville, IN, November 16, 2005
The Genetics of MS, Indiana State Chapter, National MS Society, Ft. Wayne, IN, August 30, 2005
Newly Diagnosed Dial – Up Call 1: Multiple Sclerosis; Diagnosis, Symptoms and treatment, patient
teleconference, Indiana State Chapter, National MS Society, June 8, 2005
Finding the Right Fit: Living Well with Multiple Sclerosis, Biogen patient program, Ft. Wayne, IN; May 11,
2005
Multiple Sclerosis: Diagnosis, Symptoms and Treatment, part of Moving Forward Program, Indiana State
Chapter, National Multiple Sclerosis Society, Carmel, IN, March 3, 2005
Research Update: 2005 & Beyond, Keynote Speaker, IN State Chapter, National Multiple Sclerosis
Society; Terre Haute, IN; February 9, 2005; Newburgh, IN; February 16, 2005
(3) Community Service
Not Applicable
UNIVERSITY SERVICE:
(1) University Administrative Service:
Not applicable
(2) University Committee Service:
(a)
Departmental
2014-present
Member, Academic RVU Modeling Comittee
2008-2009
Member, Review Committee for Dept. of Neurology Internal Awards Grants
2005-2009
Member, University Clinical Neurologists Board of Trustees
2004-2010
Member, Clinical Practice Committee, Department of Neurology; Committee Chair, 20052010
2002-present
Faculty Human Subject Compliance liaison, Dept. of Neurology
2002-present
Promotions and Tenure Committee, Dept. of Neurology
2002-2003
HIPPA Compliance Research Task Force
1998-2001
Chair, Department of Neurology, Faculty Salary Committee
1998-2000
Neurology Representative, IU Specialty Care Managed Care Team
1998-2000
Faculty Liaison for Department of Neurology to IUPUI Y2K Committee
1998-present
Compliance Officer, Department of Neurology, member of Indiana University School of
Medicine Compliance Committee
1997-2005
Resident Applicant Interviewer
(b) School
2012-2012
2013-present
Distance Education Committee, IUPUI Faculty Council
Chair, Data Safety Monitoring Board, Indiana Alzheimer’s
Disease Center
Student Services:
Not Applicable
OTHER PROFESSIONAL ACTIVITIES:
Not applicable
GRANTS AND FELLOWSHIPS
Tecfidera vaccination study. Biogen
rHIgM22 exaceration study. Acorda Therapeutics, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg
and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously daily in
patients with relapsing-remitting multiple sclerosis. Novartis Pharmaceutical Corporation, 1/7/2013-3/31/2015,
$396,870 (TC)
A double-blind, placebo-controlled, single ascending intravenous infusion study of rHIgM22 in patients with
multiple sclerosis. Acorda Therapeutics, Inc., 2/15/2013-2/28/2015, $263,362 (TC)
A phase 1, multicenter, randomized, double-blind, placebo-controlled, ascending single-dose study of the safety,
tolerability, and pharmacokinetics of intravenous VX15/2503 in patients with multiple sclerosis, Vaccinex,
4/10/21013-4/10/2015, $62,957 (TC)
A phase ½ randomized, dose-finding study of MEDI-551 in subjects with relapsing-remitting multiple sclerosis.
Medimmune, Inc., 7/19/2012-7/19/2016
A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the
efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis, F. Hoffmann-La Roche
Ltd. November 1, 2011- December 31, 2017, $574,625.00
A Multicenter Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing
Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, Biogen Idec Inc. August 8, 2011August 2, 2015, $241,423.00
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the
Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon B-la) in Patients
with Relapsing-Remitting Multiple Sclerosis, Biogen Idec Inc., May 24, 2011- Jan 12, 2018, $252,763.00
Follow-up to a multi-center, prospective, open-label tolerability and safety monitoring study of mitoxantrone
hygrochloride (Novatrone) in a selected cohort of Multiple Sclerosis (MS) subjects, May 1, 2012- December 31,
2012, $6,792.50
Basic and Clinical Investigations into a Novel Therapeutic Target for Multiple Sclerosis, Clinical and Translational
Sciences Collaboration in Translational Research Award, June 1, 2011-May 31, 2012, $75,000
Multicenter, randomized, double-blinded, placebo-controlled, parallel-group, dose-finding study to
evaluate the efficacy, safety, and tolerability of three doses of ACT-12880, an oral S1P1 receptor agonist,
administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis, Actelion
Corporation, Switzerland, January 7, 2010 – January 16, 2012, $316,814 (TC)
A double-blind, placebo-controlled study of the safety and efficacy of ONO-4641 in patients with
relapsing-remitting multiple sclerosis, Ono Pharmaceutical Co., Osaka, Japan, February 26, 2010 –
January 24, 2016, $253,473 (TC)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with
Relapsing-Remitting Multiple Sclerosis, Eli Lilly and Company, Indianapolis, IN, February 22, 2010 –
January 31, 2014, $373,610 (TC)
A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evalualate the
Benefits of Switching Therapy (Glatiramer Acetate of Interferon B-1a) to Natalizumab in Subjects with
Relapsing Remitting Multiple Sclerosis, Biogen-Idec, Cambridge, MA
A Phase 3, Randomized, Rater-and-Dose-Blinded Study Comparing Two Annual Cycles of Intravenous
Low-and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-la (Rebif) in
Patients with Relapsing-Remitting Multiple sclerosis Who Have Relapsed on Therapy, Genzyme
Corporation, Cambridge, MA, February 13, 1008-February 12, 2011, $243, 116, (TC)
A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with RelapsingRemitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over
placebo in a double-blind design and of a reference arm of Interferon B-1a (Avonex) in a rater-blinded
design, Teva Pharmaceutical Industries, Netanya, Israel, June 25, 2008 – Dec 31, 2015, $281, 125 (TC)
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the
Efficacy, Safety, and tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple
Sclerosis, Santofi Aventis, Beidgewater, NJ, December 1, 2008 – November 20, 2010, $131,878 (TC)
A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing
the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus
placebo in patients with relapsing-remitting multiple sclerosis, Novartis
Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, June 27, 2006 – September 30, 2011
A multinational, multicenter, randomized, parallel-group, double-blind study, to compare the efficacy,
tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20
mg/ml administered once daily by subcutaneous injection in subjects with relapsing-remitting multiple
sclerosis (MS), Netanya, Israel
Double-blind, placebo-controlled, Phase I, dose-escalation study of the safety of a single dose of
RTL 1000 in subjects with relapsing-remitting or secondary progressive multiple sclerosis, site PI: David
H. Mattson, MD, PhD, Artielle Immuno Therapeutics, Inc., Tigard, Oregon, 6/20/06 – 6/6/08, $72,844
(TC).
MS-F203 Double-blind, placebo-controlled, 21-week, parallel group study to evaluate safety and efficacy
of oral Frampridine SR (10 mg. b.i.d.) in subjects with multiple sclerosis, site PI: David H. Mattson, MDPhD, Acorda Therpeutics, Hawthorne, NY, 7/15/05 -12/31/10, $166,638 (TC).
Past Research Grants:
International, randomized, multi-center, phase IIIb study in patients with relapsing remitting multiple
sclerosis comparing: double-blinded the safety, tolerability, and efficiency of Betaseron 250 mcg and
Betaseron 500 mcg, both given subcutaneously every other day, rater-blinded the safety, tolerability, and
efficiency of Betaseron 250 mcg s.c.e.o.d. with Copaxone 20mg s.c. once daily over a treatment period of
104 weeks; Site PI: David H. Mattson, MD-PhD, Berlex Laboratories, Inc, Pine Brook, NJ; $371,125 (TC)
A Phase Il/Ill, randomized double-blind, parallel group, placebo-controlled multi-center study to evaluate
the safety and efficiency of rituximab in adults with primary progressive multiple sclerosis; Site PI: David
H. Mattson, MD-PhD, Genetech Corp, CA; $419,245 (TC)
Prospective, open-label tolerability and safety monitoring study of Novantrone (mitoxantrone for injections
concentrate) in a selected cohort of multiple sclerosis patients; Immunex Protocol #031.0007, Site PI:
David H. Mattson, MD-PhD, Immunex Corp., Seattle, WA, 5/01-present $33,813 (TC)
A randomized, double-blind, placebo-controlled study to evaluate the tolerability and efficiency of NBI5788 in patients with relapsing remitting multiple sclerosis patients: Site PI: David H. Mattson, MD-PhD,
Pharmaceutical Research Associates, Inc., Lenexa, KS; Neuroscience Biosciences, Inc., San Diego, CA;
7/31/03-7/31/07; $176,688 (TC)
A multi-center randomized, double-blind, parallel group study to evaluate the efficiency, tolerability, safety
of 40 mg of Copaxone in the treatment of relapsing-remitting multiple sclerosis: Site PI: David H. Mattson,
MD-PhD, Teva Neuroscience, Inc., Kansas City, MO; 10/20/03-9/22/06,; $187,872 (TC)
A randomized, double-blind, placebo controlled, parallel group, multi-center study to determine the safety
and efficacy of natalizumab, when added to Avonex (Inerferon beta-la), in subjects with relapsing
remitting multiple sclerosis, Site PI: David H. Mattson, MD-PhD, Biogen Corp., Cambridge, MA; 10/019/04
A randomized, rater-blinded, multi-center, parallel group study comparing the efficiency and safety of
Betaseron 250 mcg subcutaneously every other day with Avonex 30 mcg intramuscularly once per week
in relapsing remitting multiple sclerosis patients previously treated with Avonex ; Site PI: David H.
Mattson, MD-PhD, Berlex Laboratories, Inc., Pine Brook, NJ; 8/26/03-11/25/06; $803,012 (TC)
An open label study evaluating the ability of multiple sclerosis patients on chronic Rebif 44 mcg tiw
treatment to mount an immunological response to influenza vaccine; Site PI: David H. Mattson, MD-PhD,
Serono, Inc., Rockland, MA; 8/31/03-8/31/04; $18,375 (TC)
A randomized, multi-center, parallel group, open-label study comparing the tolerability of Rebif injection
with and without the use of Rebiject Mini in MS Patients, Site PI: David H. Mattson, MD-PhD, Serono
Corp., Norwell, MA, 2/02-1/03 $24,000 (TC)
Safety, tolerance, and pharmacodynamic study of repeated single oral doses of E2101 in patients with
muscle spasticity due to multiple sclerosis, Site PI: David H. Mattson, MD-PhD, Easai, Inc., Teaneck,NY,
1/01-present
Randomized, double-blind, placebo-controlled, ascending dose safety, tolerance, and magnetic
resonance imaging study of J695 in patients with multiple sclerosis, Site PI: David H. Mattson, MD-PhD,
Wyeth-Ayerst Research, Philadelphia, PA, 3/01-present
An open label, randomized, multi-center, comparative, parallel group study of Rebif 44 mcg administered
three times per week by subcutaneous injection, compared with Avonex 30 mcg administered once a
week by intravenous injection in the treatment of relapsing-remitting multiple sclerosis; Site PI: David H.
Mattson, MD-PhD, Serono Laboratories, Inc., Norwell, MA; 9/23/99-12/30/01; $308,080 (TC), 10 patients
enrolled
A multi-national, multi-center, double-blind, placebo controlled study to evaluate the efficacy, tolerability
and safety of glatiramer acetate for injection in primary progressive multiple sclerosis patients; site P1:
David H. Mattson, MD, PhD; Teva Pharmaceuticals USA, Sellersville, PA; 10/1/98 — 9/30/02, $205,500
(DC). $256,875 (TC), 20 patients enrolled
A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Avonex in the treatment
of secondary progressive multiple sclerosis (MS); Site PI: David H. Mattson, MD-PhD; Biogen,
Cambridge, MA; 11/97-6/00, $82,560 (DC) $103,200 (TC), 11 patients enrolled. Extension phase 6/006/05; $23.350 (TC), 8 patients enrolled
A multinational, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy,
tolerability, and safety of 2 doses (5 mg and 50 mg) of glatiramer acetare orally administered in relapsingremitting multiple sclerosis patients; Site PI: avid H. Mattson, MD-PhD; Teva Pharmaceuticals USA,
Sellersville, PA; 11/3/99-12/30/01; 120,750 (TC), 4 patients enrolled
A 12 week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy and
safety of donepezil hydrochloride (E2020) in the treatment of cognitive impairment in patients with
multiple sclerosis; Site PI: David H. Mattson, MD-PhD, Pfizer, Inc., New York, NY; 11/4/99-71/01
A multi-center, open-label pharmacodynamic study of Avonex and Rebif in multiple sclerosis subjects
after first injection and after 12 to 18 months of therapy, site PI: David H. Mattson, MD-PhD; Biogen,
Cambridge, MA; 6/99-5/00, $15,000 (TC), 10 patients enrolled
Pilot MRI study PEG-Intron (SCH 54031) in ambulatory patients with relapsing remitting multiple
sclerosis, Site PI: David H. Mattson, MD-PhD; Schering-Plough Research Institute, Kenilworth, NJ; 6/999/00, #97,760 (DC), $114,699 (TC), 3 patients enrolled
Glatiramer Acetate Auto-Injection: ease of use and safety trial, Site PI: David H. Mattson, MD-PhD; Teva
Pharmaceuticals USA, Kulpsville, PA; 1/01-present. Two patients enrolled
A double-blind, placebo-controlled, dose-determination, safety, tolerability and efficacy study of
intravenous Antegren in patients with multiple sclerosis during an acute exacerbation; Site PI: David H.
Mattson, MD-PhD; Athena Neuroscience, Inc., South San Francisco, CA; 1/98-3/99;$20,030 (TC), 1
patient enrolled
MS Trac: A registry of multiple sclerosis treatments and care; Site PI: David H. Mattson, MD-PhD; Biogen,
Cambridge, MA; 1/1/99-12/31/02; (DC), $4,281 (IC), 15 patients enrolled
Fractionated reaction time as a secondary outcome measure in multiple sclerosis clinical studies. PI:
David H. Mattson, MD-PhD, National MS Society, 11/1/98-10/31/99, $24, 945 (DC), $27,500 (TC)
Phase I, randomized, double-blinded, placebo-controlled, rising single-dose study of subcutaneous rhulL10 (SCH 52000) in patients with relapsing-remitting multiple sclerosis with gadolinium-enhanced MRI
evidence of disease activity, PI: David H. Mattson, MD-PhD; Schering-Plough Research Institute,
Kenilworth, NJ; 1/97/-6/98; $81,171 (TC)
A randomized, double-blinded, placebo-controlled, rising multiple-dose phase lb study of subcutaneous
rhu IL- 10 (SCH 520001) in patients with multiple sclerosis; Site PI: David H. Mattson, MD-PhD; ScheringPlough Research Institute, Kneilworth, NJ; 8/98-12/98; $8,000 (TC)
Human leukocyte antigren expression in multiple sclerosis; Site PI: David H. Mattson, MD-PhD; National
Institutes of Health BRSG PHS S7RR05403-28, 1/1.90; $11,000 (TC)
Buswell Fellowship Award, University of Rochester, Academic Year 1990-91, $10,000 salary support (TC)
Evaluation and treatment of sexual dysfunction in multiple sclerosis patients, PI: David H. Mattson, MDPhD; Wyman Potter Foundation, 10/1/92-9/30/93, $4,000 (TC)
T cell diversity and specificity in multiple sclerosis, PI: David H. Mattson, MD-PhD; National Multiple
Sclerosis, JF 2054-A-1, Harry Weaver Neuroscience Scholar Award, 7/1/91-6/30/97; $495,352 (TC)
Pulse steroids and bone density in patients with multiple sclerosis, PI: David H. Mattson, MD-PhD;
National Multiple Sclerosis Society pilot award, 5/1/94-10/31/96; $18,800 (TC)
The effect of pulse steroids on bone density in multiple sclerosis, PI: David H. Mattson, MD-PhD; Wyman
Potter Foundation, 6/1/94-5/30/95; $4,000 (TC)
Long term, open-label treatment IND study to further evaluate the safety of Copaxone and to extend its
availability to patients with relapsing-remitting multiple sclerosis, PI: David H. Mattson, TEVA/Lemrnon
Pharmaceuticals, Kulpsville, PA; 6/20/95-4/1/97, two patients enrolled
A randomized, double-blind, placebo-controlled, phase 3 Study of Roquinimex (Linomide) in relapsingremitting and secondary progressive multiple sclerosis, PT: Andrew Goodman, Co-Investigator: David
Mattson. Pharmacia, Lund, Sweden; 6/96-7/97
A randomized, double-blind, placebo-controlled study of AVONEX (Interferon Beta-la) in the treatment of
subjects at high risk for development of multiple sclerosis following the first onset of an isolated
demyelinating event, PI: Andrew Goodman, Co-PI: David H. Mattson, MD-PhD; Biogen Corporation,
Cambridge, MA;6/96-present
PRINT AND ELECTRONIC PUBLICATIONS:
[Il] Research, Scholarship, or Creative Activities (Refereed):
1. Hachey DL, Kreek MJ, Mattson DH: Quantitation of methadone in biological fluids using
deuterium labeled methadone and glc-chemical-ionization mass spectrometry. J. Pharm. Sci.
66:1579-1582, 1977.
2. Mattson DH, Roos RP, Arnason BGW: Isoelectric focusing of IgG eluted from multiple sclerosis
and Subacute sclerosing panencephalitis brains. Nature 287:335-337,1980.
3. Mattson DH, Roos RP, Arnason BGW: Immunoperoxidase staining of CSF IgG in isoelectric
focusing gels: A sensitive new technique. I. Neurosci. Methods 3:67-75, 1980.
4. Whitacre CC, Mattson DH, Paterson PY, Roos Rp, Peterson Dj, Arnason BGW: Cerebrospinal
fluid and serum oligoclonal IgG bands in rabbits with experimental allergic encephalomyelitis.
Neurochem. Res6:87-96, 1981.
5. Mattson DH, Roos RP, Arnason BGW: Comparison of agar gel electrophoresis and isoelectric
focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann. Neurol. 9:34-41,
1981.
6. Whitacre C.C. Mattson DH, Day E, Roos RP, Arnason BGW, Peterson DJ, Paterson PY:
Oligoclonol IgGin rabbits with experimental allergic encephalomyelitis: Non-reactivity of the
bands with sensitizing neural antigens, Neurochem. Res. 7: 1209-1221, 1982.
7. Mattson DH, Roos RP, Hopper JE, Arnason BGW: Light chain composition of CSF oligoclonal
IgG bands in multiple sclerosis and subacute sclerosing panencephalitis. J. Neuroimmunol.
3:63-76, 1982.
8. Mattson DH, Roos RP, Arnason BGW: Oligoclonal IgG in multiple sclerosis and subacute
sclerosing panencephalitis brains. J. Neuroimmunol. 2:261-276, 1982.
9. Mattson DH, McFarlin DE, Mora C, Zaninovic V: Central nervous system lesions detected by
magnetic resonance imaging in an HTLV-I antibody positive symptomless individual. Lancet i:
49. 1987.
10. Mattson DH, Handy DE. Bradley DA, Coligan JE, Cowan EP, Biddison WE: DNA sequence of
the genes that encode the CTL-defined HLA-A2 variants M7and DK1. Immunogenetics 26:190192, 1987.
11. Beall SS, Lawrence JV, Bradley DA, Mattson DH, Singer DS, Biddison WE, Beta chain gene
rearrangements and V_beta gene usage in DPw2 specific T cells. J. Immunol. 139: 123201325, 1987.
12. Mattson DH, Shimojo N, Cowan EP, Baskin JJ, Turner RV, Shvetsky B, Coligan JE, Maloy WL,
Bidlison WE: Differential effects of amino acid substitutions in the beta sheet floor and alpha
two helix of HLA-A2 on all reactive versus viral peptide-specific CTL. J. Immunol. 143:11011107, 1989.
13. Shimojo N, Anderson RW, Mattson DH, Turner RV, Shvetsky B, Coligan JE, Biddison WE, The
kinetics of peptide binding to HLA-A2 complex can be determined by amino acid side chains on
the floor of the peptide binding grove. Int. Immunology 2:193-200, 1990.
14. Jacobson S, Gupta A, Mattson DH, Mingioli F, McFarlin DE: Immunologic studies in tropical
spactic paraparaesis. Ann. Neurol. 27:14+-156, 1990.
15. Banki K, Maceda J, Hurley F. Ablonczy E, Mattson DH, Szegedy L, Hung C, Perl A: Human Tcell lymphotrophic virus (HTLV) related endogenous sequence. HRES-1, encodes 28-KDa
protein: A possible autoantigen for HTLV-1 gag-reactive autoantibodies. PNAS 89:1939-1943,
1992.
16. Schiffer RB, Giang DW, Mushlin A, Joy S, Ketonen L, Kido D, Goodman AD, Mattson DH,
Mooney. Perils and pitfalls of MR scanning in the diagnosis of multiple sclerosis. J.
Neuroimaging 3:81- 88, 1993.
17. Abreu A, Bowers K, Mattson D, Gaspari A: Linear IgA bullous dermatosis in association with
multiple sclerosis. J Am Acad Derm 3l:797-799, 1994.
18. Banki K, Colombo E, Sia F, Halladay D, Tatum AH, Massa PT, Mattson DH, Phillips PE, Perl A:
Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis.
J Exp Med 180: 1649-1663, 1994.
19. Giang DW. Grow VM. Mooney C, Mushlin Al, Goodman AD, Mattson DH, Schiffer RB: Clinical
diagnosis of multiple sclerosis: The impact of magnetic resonance imaging and ancillary testing.
Arch Neurology 51:61-66, 1994.
20. Mattson D, Petrie M, Srivastava DK, McDermott M: Multiple sclerosis: sexual dysfunction and
its response to medications. Arch Neurol 52:862-868, 1995.
21. Barned S, Goodman AD, Mattson DH: Frequency of anti-nuclear antibodies in multiple
sclerosis. Neurology 45:384-385, 1995.
22. Mattson D: Antinuclear antibodies in multiple sclerosis [reply from the author to letters to editor].
Neurology 45:2300-2301. 1995.
23. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid
pulse and osteoporosis in multiple sclerosis. Arch Neurol 53:753- 757, 1996.
24. Giang D, Goodman A, Schiftèr R, Mattson D, Petrie M, Cohen N, Ader R: Conditioning of
cyclophosphamide- induced leukopenia in humans. J. Neuropsych & Clin Neurosci. 8:194-201,
1996.
25. Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, Scheid EA,
Dudman JT, McDermott MP. The measurement of ambulatory impairment in multiple sclerosis.
Neurology 49:1419-1424, 1997.
26. Collard RC, Koehler RPM, Mattson DH. Frequency and significance of antinuclear antibodies in
multiple sclerosis. Neurology 49:857-861, 1997.
27. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in multiple sclerosis
patients treated with interferon beta lb, Arch Neurol 57:1169-1170, 1997.
28. Becker KG, Mattson DH, Powers JM, Gado AM, Biddison WE. Analysis of a sequenced cDNA
library from multiple sclerosis lesions. J. Neuroimmunol. 77:27-38, 1997.
29. Mushlin Al, Mooney C, Holloway RG, Detsky AS, Mattson DH, Phelps CE. The costeffectiveness of magnetic resonance imaging for patients with equivocal neurologic symptoms.
Int J Tech Assess Hlth Care 12:21-34, 1997.
30. Guthikonda P, Baker J, Mattson DH, Interferon-beta-lb (IFN-B) decreases nitric oxide (NO)
production by a human astrocytoma cell line. J. Neuroimmunol. 82: 133-139, 1998.
31. Schrager P, Custer A, Kazarinova K, Rasband M, Mattson DH. Nerve conduction block by nitric
oxide that is mediated by the axonal environment. J. Neurophysiol. 79:529-536, 1998.
32. Mattson DH. Antinuclear antibodies and MRI activity in multiple sclerosis [reply to letter to
editor]. Neurology 5 1:650, 1998.
33. Mock D, Powers JM, Goodman, AD, Blumenthal SR, Ergio N, Baker JV, Mattson DH, Assouline
JG, Bergey EJ, Chen B, Epstein LG, Blumberg BM. Association of human herpes virus 6 with
the demyelinative lesions of progressive multifocal leukoencephalopathy. J. Neuroimmunol.
1999; 5:363-373.
34. Apache RR, Mattson DH, Jackson D. Assessing lower extremity function in multiple sclerosis
patients by reaction time. Clinical Kinesiology. 2001; 55: 13-19.
35. Apache RR, Jackson D, Mattson DH. Use of reaction and movement time as a measure of
lower extremity functioning in multiple sclerosis. Clinical Kinesiology. 2002; 56(3): 35-41.
36. Apache RR, Jackson D, Mattson DH. Responsiveness of choice reaction and movement time in
multiple sclerosis. Accepted. Clinical Kinesiology, 2005; 59 (summer)
37. Lowe MJ, Phillips MD, Lurito JT, Mattson DH, Dzemidzic M, Matthews VP. Multiple Sclerosis:
low frequency temporal BOLD fluctuations indicate reduced functional connectivity- initial
results. Radiology. 2002; 224: 184-192.
38. Mattson, DH, Update on the diagnosis of multiple sclerosis (MS), Expert Rev.
Neurotherapeutics, 2002; 2(3): 319-328.
39. Ali L, Biller J, Mattson D, Roos K. Case Report: Saggital sinus thrombosis as the first clinical
manifestation of metastatic breast cancer. Seminars Cerebrovascular Dis. Stroke 2003; 3: 246-
251.
40. Yadav V, Bourdette DN, Bowen J, Lynch SG, Mattson D, Premingerova J, Bever C, Simon JH,
Goldstein A, Burrows G, Offner H, Fero A, Vandenbark A, Recombinant T-cell receptor ligand
(RTL) for the treatment of Multiple Sclerosis. A double-blind, placebo-controlled, Phase I, dose
escalation study. Autoimmune Diseases. 2012:1-11
41. Mattson DH, Lisak RP, Jones DE. Writeclick : Editors Choice. The American Academy of
Neurology’s top five Choosing Wisely recommendations. 2013;81: 1022-1023
42. Mazda M, Brosch J, Wiens, A, Bonin, Kamer, Mattson D. Snook R. A case of natalizumab associated progressive multi-focal leukoencephalopathy with repeated negative CSF JC virus
testing, Int J Neurosci, 2013:1-5
43. Miller A, Cohen B, Krieger S, Markowitz C, Mattson D, Tselentis, H, Constructing an adaptive
care model for the management of disease-related symptoms throughout the course of multiple
sclerosis-- Performance improvement CE. Multiple Sclerosis. 2013
Abstracts:
1. Mattson DH, Blomberg DJ: Separation of creatinine phophokinase isoenzymes by vertical acrylamide
disc gel electrophoresis. Clin. Res. 23:549A, 1975.
2. Noronha AB, Mattson DH, Sundareson N, Roos RP, Arnason BGW: Cerebrospinal fluid (CSF)
oligoclonal IgG in central nervous system neoplasia. Neurology 31:43, 1981.
3. Oger J J-f, Mattson DH, Roos RP, Antel JP, Arnason BGW: Isoelectric focusing (IEF) of IgG secreted
by human peripheral blood lymphocytes (PBL) in multiple sclerosis and controls. Neurology 31:144.
1981.
4. Mattson DH, Turner R, McFarlin D, Biddison W: Regulation of human leukocyte antigen (HLA)
expression in multiple sclerosis (MS). Ann. Neurol. 26:150, 1989.
5. Goodman AD, Giang D, Mattson DH, Armer J, Schiffer R: Minimal toxicity associated with monthly
pulses of cyclophosphamide in the treatment of chronic progressive multiple sclerosis: Preliminary
observations. Ann. Neurol., 28:245, 1990.
6. Mattson DH, Montgomery J, Moyer A: Regulation of expression of human leukocyte antigens (HLA)
on an oligodendroglioma cell line. Ann. Neurol., 30:304, 1991.
7. Mattson DH: Regulation of HLA Expression on an oligodendroglioma cell line by TGF 2. Ann.
Neurology, 34:274, 1993.
8. Mattson DH, Guthikonda P: Modulation of human immune function by nitric oxide. Presented. First
International Conference on Biochemistry and Molecular Biology of Nitric Oxide. Los Angeles, CA,
July 16-21, 1994.
9. Mattson DH, Guthikonda P: Modulation of mitogen-induced human lymphocyte proliferation by nitric
oxide. Presented. Fourth International Conference on Neuroimmunology, Neuroinfections,
Neuroimage. St. Petersburg, Russia, May 25-27, 1995.
10. Barrett K, Guthikonda P, Goodman A, Mattson D: The effect of in vitro and in vitro interferon-beta-lb
on immunoglobulin G synthesis by peripheral blood lymphocytes. Neurology 46:A136-A137, 1996.
11. Mock D, Blumenthal S, Goodman A, Mattson D, Powers J, Assouline I, Blumberg B. Association of
human herpes virus-6 (HHV6) with the neuropathologic lesions in progressive multifocal
leukoencephalopathy (PML) and multiple sclerosis (MS). Presented. Infectious Diseases Society of
America 35th Annual Meeting. 1997.
12. Mihai C, Schwid SR, Petrie MD, Goodman AD, Mattson DH. Selection criteria for interferon beta - lb
in multiple sclerosis patients. Neurology 48:A348, 1997.
13. Apache RR, Mattson DH, Surburg PR, Jackson D. Correctional fractional reaction times in
ambulatory multiple sclerosis patients. Presented, Neuroscience Meetings, Los Angels, CA, 11/98.
14. Jackson D, Mattson DH. Steroid responsiveness of sexual dysfunction in multiple sclerosis.
Presented, Consortium of MS Centers meeting, Cleveland, OH, 10/2/98-10/4/98. Multiple Sclerosis
4:459, 1998.
15. Lowe MI, Phillips MD, Mattson DH, Mathew VP, Lurito IT, Dzemidzic M, Srinavasan R. Resting state
BOLD fluctuations reflect impaired functional connectivity in multiple sclerosis. Submitted.
16. Phillips MD, Lowe MI, Mattson DH, Mathews VP, Lurito JT, Dzemidzic M. Loss of functional
connectivity in patient with advanced multiple sclerosis (MS). Submitted.
17. Apache RR, Mattson DH, Jackson DG. Assessing lower extremity function in multiple sclerosis by
reaction time. Presented. Consortium of MS Center Meeting, Halifax, Nova Scotia, June, 2000.
18. Mahmoud SYM, Phillips M.D., Mattson DH, Mathews VP, Apparent diffusion coefficient of the normal
appearing white matter in multiple sclerosis and in normal subjects: The effect of aging. Presented.
American Society of Neuroradiology, Vancouver, Canada, May 17, 2002.
19. Mattson DH, Lowe M, Phillips M, Mathews V, Lurito J, Dzemidzic M, Srinivasan R. Loss of Functional
connectivity in multiple sclerosis by functional MRI analysis, presented, American Neurological
Association meeting, Chicago, IL, October 1, 2001.
20. Apache RR, Jackson DG, Mattson DH, Responsiveness of reaction time in MS, presented, Society
for Neuroscience, San Diego, CA, November 11, 2001.
21. Yadav V, Bourdette D, Bower JD, Lynch SG, Mattson D, etal., Recombinant T cell receptor ligand
(RTL) for the treatment of multiple sclerosis: Report of a phase 1 clinical trial. Neurology 74 (suppl.
2):A293-A294, 2010.
22. Comer AD, Mattson DH. Effect of dalfampridine on subjective domains of functioning in patients with
multiple sclerosis. Presented. Consortium of MS Centers annual meeting, Indianapolis, IN. 5/29/2015
[II] Research, Scholarship, Or Creative Activities (Non-Refereed):
1. Roos RP, Mattson DH: Antigen and antibody studies in demyelinating disease. in MS: Present
and Future. Scarlab and Mathews WB, eds. Plenum Publishing Corp., New York, p.55, 1984.
2. McFarlin DE, Gupta A, Mattson D, Harris I, Reuben IS, Jacobsen 5: Immunologic and virologic
studies in HAM/TSP. in Human Retrovirology: HTLV. Blattner WA, ed. Raven Press, New York,
NY, pp. 65-67, 1990.
3. Mattson DH: Book review of Trends in Neuroimmunology, MG Marrosu, C Cianchetti, B Tavolato
(eds), Arch Neurol 1991; 48:129.
4. Mattson DH: The pathogenesis of multiple sclerosis. In Wolf I, ed. Mastering Multiple Sclerosis,
Academy Books, Ruland, Vt., pp. 370-398, 1996,
5. Mattson DH: Sexual dysfunction in MS. In: Rudick R, Paty D, Stuart W, Scheinberg L, eds.
Multiple Sclerosis: Clinical Issues, 2(3): 10-13, 1995,
6. Mattson DH: Book review of Multiple Sclerosis. Its Impact from Childhood to Old Age, by Bauer
HJ, Hanefeld FA. Arch Neurol 1996;53:118-119,
7. Mattson DH: Post-infectious encephalomyelitis. In: Gilman S. Goldstein GW, Waxman SC. eds.
Neurobase. LaJolla, CA: Arbor Publishing, 1995,1996,1997,1998,1999 eds,
8. Mattson DH, Iwamoto F: Progressive multifocal leukoencephalopathy. In Gilman 5, Goldstein
GW, Waxrnan SC, eds. Neurobase, La Jolla, CA: Arbor Publishing, 1996, 1997, 1998, 1999,
2002 eds,
9. Mihai C, Mattson DH: Ch. 48. Myelitis and myelopathy. In: Griggs R, Joynt R, eds. Clinical
Neurology.Philadelphia, PA: Lippincott-Raven, 1997. p. 1-31; major revision, 2002,
10. Mattson DH: Evaluation and treatment of the patient with demyelinating and dysmyelinating
diseases. Batjer HH, Lot’tus CM, eds., Textbook of Neurological Surgery,
11. Mattson DH: Multiple Sclerosis, in Roos K ed. Nerologic Disorders and Pregnancy. Continuum,
2000: 6: 64-78,
12. Mattson DH: Book review of Advances in Multiple Sclerosis Clinical Research and Therapy,
Frederickson and Link H (eds). Neurology,
13. Mattson DH: Ultimate Novedades. in Particular, the magazine of the Association de Lucha contra
Ia Esclerosis Multiple of Argentina (Argentinian Multiple Sclerosis Society). 2001; 3:4.6
14. Mattson DH, Kolar OJ: Approach to the Patient with Acute Sensory Loss. in Biller J (ed), Practical
Neurology, 2nd edition, Lippincott Wilkins & Wilkins, Philadelphia, PA, 2002, pp. 221-232, revised
for 3rd edition, 2007
15. Mattson DH, Disorders that Mimic Multiple Sclerosis, MS Quarterly Report, 21(3): 12-16,- Fall,
2002
16. Mattson DH, Alphabet Soup — A personal, evolving mostly evidence based and logical,
sequential approach to the “ABCNR” drugs in multiple sclerosis (MS), Seminars in Neurology, 22:
17-25, 2002
17. Mattson DH, 7 Myths about Multiple Sclerosis. Bottom Line/Health, 17(12):l 1-12, 2003
18. Mattson DH, Wegner Granulomatosis, In: Gilman S. Goldstein GW, Waxman SG, eds.
Neurobase, Lajolle, CA; Arbor Publishing, 2003, 2005, 2007, 2009
19. Mattson DH, Multiple Sclerosis: Many have it and don’t know it. Bottom Line/Personal, 2005;
26:11-13.
20. Mattson, DH, Multiple Sclerosis in Women, in Fife R, ed. ACP Manual of Women’s Health,
Philadelphia, PA: ACP Press
21. Mattson, DH, Technical Editor for Kalb R, Holland N, Geisser, B. Multiple Sclerosis for Dummies,
Hoboken, NJ: Wiley Publishing, Inc., 2007
22. Mattson DH, Auld E, Disorders That Mimic Multiple Sclerosis : MS Quarterly Report, 28 (4): 1519, Winter, 2009
23. Ford CC, Jeffery DR, Mattson DH, The Science of MS Management. Beyond Monoclonals: Novel
Mechanisms for New MS Therapies. Delaware Media Group, Spring 2012, p.3-15
24. Mattson, DH, Commentary on : The magnetic resonance imaging “rule of five”: Predicting the
occurrences of relapses. In Multiple Sclerosis monitor and Commentary. 2013; Fall, p.5
25. Bever CT, Cohen BA, Gettings EJ, Mattson DH. NeuroPI: Multiple sclerosis symptom
assessment. American Academy of Neurology Maintenance of Certification module, released online 12/5/2014
Date
Signature
07/08/2015
David H. Mattson, MD, PhD